

RECEIVED
CENTRAL FAX CENTER

APR 06 2006

Attorney Docket No.: 6510.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stennicke et al.

Serial No.: 10/617,500

Group Art Unit: 1656

Filed: July 11, 2003

Examiner: Schnizer, Holly G.

For: TF Antagonist

**CERTIFICATE OF FACSIMILE TRANSMISSION
571-273-8300**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement of March 7, 2006

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Holly G. Schnizer, fax number 571-273-8300.

Respectfully submitted,

Date: April 6, 2006

/Csaba Attila Szakolczai/
Csaba Attila Szakolczai
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

RECEIVED
CENTRAL FAX CENTER

APR 06 2006

Please use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Attorney Docket No. 6510.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stennicke et al.

Confirmation Number: 3991

Application No.: 10/617,500

Group Art Unit: 1656

Filed: July 11, 2003

Examiner: Schnizer, Holly G.

For: TF ANTAGONIST

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed March 7, 2006, which sets forth a restriction requirement, please consider the provided remarks as follows:

Amendments to the Claims are reflected in the **Listing of Claims**, which begins on page 2 of this paper.

Remarks concerning the Office Action and the claim amendments begin on page 7 of this paper.